ID   PRPS1_HUMAN             Reviewed;         318 AA.
AC   P60891; B1ALA8; B2R6T7; B4DNL6; D3DUX6; P09329;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=Ribose-phosphate pyrophosphokinase 1;
DE            EC=2.7.6.1;
DE   AltName: Full=PPRibP;
DE   AltName: Full=Phosphoribosyl pyrophosphate synthase I;
DE            Short=PRS-I;
GN   Name=PRPS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lymphoblast;
RX   PubMed=2155397; DOI=10.1093/nar/18.1.193;
RA   Roessler B.J., Bell G., Heidler S., Seino S., Becker M., Palella T.D.;
RT   "Cloning of two distinct copies of human phosphoribosylpyrophosphate
RT   synthetase cDNA.";
RL   Nucleic Acids Res. 18:193-193(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1650777;
RA   Sonoda T., Taira M., Ishijima S., Ishizuka T., Iizaka T., Tatibana M.;
RT   "Complete nucleotide sequence of human phosphoribosyl pyrophosphate
RT   synthetase subunit I (PRS I) cDNA and a comparison with human and rat
RT   PRPS gene families.";
RL   J. Biochem. 109:361-364(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-41 (ISOFORM 1).
RX   PubMed=1314091; DOI=10.1016/0167-4781(92)90521-Z;
RA   Ishizuka T., Iizasa T., Taira M., Ishijima S., Sonoda T., Shimada H.,
RA   Nagatake N., Tatibana M.;
RT   "Promoter regions of the human X-linked housekeeping genes PRPS1 and
RT   PRPS2 encoding phosphoribosylpyrophosphate synthetase subunit I and II
RT   isoforms.";
RL   Biochim. Biophys. Acta 1130:139-148(1992).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-33; 85-96; 164-176; 205-214; 236-260 AND
RP   303-318, CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (JUL-2009) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 244-260 AND 303-318, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH AMP, SUBUNIT,
RP   AND MUTAGENESIS OF SER-132; ASN-144 AND TYR-146.
RX   PubMed=16939420; DOI=10.1042/BJ20061066;
RA   Li S., Lu Y., Peng B., Ding J.;
RT   "Crystal structure of human phosphoribosylpyrophosphate synthetase 1
RT   reveals a novel allosteric site.";
RL   Biochem. J. 401:39-47(2007).
RN   [12]
RP   VARIANTS PRPS1 SUPERACTIVITY SER-114 AND HIS-183.
RA   Roessler B.J., Palella T.D., Heidler S., Becker M.A.;
RT   "Identification of distinct PRPS1 mutations in two patients with X-
RT   linked phosphoribosylpyrophosphate synthetase superactivity.";
RL   Clin. Res. 39:267A-267A(1991).
RN   [13]
RP   VARIANTS PRPS1 SUPERACTIVITY HIS-52; SER-114; ILE-129; HIS-183;
RP   VAL-190 AND GLN-193.
RX   PubMed=7593598; DOI=10.1172/JCI118267;
RA   Becker M.A., Smith P.R., Taylor W., Mustafi R., Switzer R.L.;
RT   "The genetic and functional basis of purine nucleotide feedback-
RT   resistant phosphoribosylpyrophosphate synthetase superactivity.";
RL   J. Clin. Invest. 96:2133-2141(1995).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-203; GLY-219 AND ASP-231.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANTS ARTS PRO-133 AND PRO-152.
RX   PubMed=17701896; DOI=10.1086/520706;
RA   de Brouwer A.P.M., Williams K.L., Duley J.A., van Kuilenburg A.B.P.,
RA   Nabuurs S.B., Egmont-Petersen M., Lugtenberg D., Zoetekouw L.,
RA   Banning M.J.G., Roeffen M., Hamel B.C.J., Weaving L., Ouvrier R.A.,
RA   Donald J.A., Wevers R.A., Christodoulou J., van Bokhoven H.;
RT   "Arts syndrome is caused by loss-of-function mutations in PRPS1.";
RL   Am. J. Hum. Genet. 81:507-518(2007).
RN   [16]
RP   VARIANTS CMTX5 ASP-43 AND THR-115.
RX   PubMed=17701900; DOI=10.1086/519529;
RA   Kim H.-J., Sohn K.-M., Shy M.E., Krajewski K.M., Hwang M., Park J.-H.,
RA   Jang S.-Y., Won H.-H., Choi B.-O., Hong S.H., Kim B.-J., Suh Y.-L.,
RA   Ki C.-S., Lee S.-Y., Kim S.-H., Kim J.-W.;
RT   "Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate
RT   synthetase enzyme critical for nucleotide biosynthesis, cause
RT   hereditary peripheral neuropathy with hearing loss and optic
RT   neuropathy (cmtx5).";
RL   Am. J. Hum. Genet. 81:552-558(2007).
RN   [17]
RP   VARIANTS DFNX1 ASN-65; THR-87; THR-290 AND ARG-306.
RX   PubMed=20021999; DOI=10.1016/j.ajhg.2009.11.015;
RA   Liu X., Han D., Li J., Han B., Ouyang X., Cheng J., Li X., Jin Z.,
RA   Wang Y., Bitner-Glindzicz M., Kong X., Xu H., Kantardzhieva A.,
RA   Eavey R.D., Seidman C.E., Seidman J.G., Du L.L., Chen Z.Y., Dai P.,
RA   Teng M., Yan D., Yuan H.;
RT   "Loss-of-function mutations in the PRPS1 gene cause a type of
RT   nonsyndromic X-linked sensorineural deafness, DFN2.";
RL   Am. J. Hum. Genet. 86:65-71(2010).
RN   [18]
RP   VARIANT LEU-142, AND CHARACTERIZATION OF VARIANT LEU-142.
RX   PubMed=22246954; DOI=10.1002/ajmg.a.34428;
RA   Moran R., Kuilenburg A.B., Duley J., Nabuurs S.B., Retno-Fitri A.,
RA   Christodoulou J., Roelofsen J., Yntema H.G., Friedman N.R.,
RA   van Bokhoven H., de Brouwer A.P.;
RT   "Phosphoribosylpyrophosphate synthetase superactivity and recurrent
RT   infections is caused by a p.Val142Leu mutation in PRS-I.";
RL   Am. J. Med. Genet. A 158A:455-460(2012).
RN   [19]
RP   VARIANT PRO-16.
RX   PubMed=25491489; DOI=10.1186/s13023-014-0190-9;
RA   Almoguera B., He S., Corton M., Fernandez-San Jose P.,
RA   Blanco-Kelly F., Lopez-Molina M., Garcia-Sandoval B., Del Val J.,
RA   Guo Y., Tian L., Liu X., Guan L., Torres R.J., Puig J.G.,
RA   Hakonarson H., Xu X., Keating B., Ayuso C.;
RT   "Expanding the phenotype of PRPS1 syndromes in females: neuropathy,
RT   hearing loss and retinopathy.";
RL   Orphanet J. Rare Dis. 9:190-190(2014).
CC   -!- FUNCTION: Catalyzes the synthesis of phosphoribosylpyrophosphate
CC       (PRPP) that is essential for nucleotide synthesis.
CC   -!- CATALYTIC ACTIVITY: ATP + D-ribose 5-phosphate = AMP + 5-phospho-
CC       alpha-D-ribose 1-diphosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by magnesium and inorganic phosphate.
CC   -!- PATHWAY: Metabolic intermediate biosynthesis; 5-phospho-alpha-D-
CC       ribose 1-diphosphate biosynthesis; 5-phospho-alpha-D-ribose 1-
CC       diphosphate from D-ribose 5-phosphate (route I): step 1/1.
CC   -!- SUBUNIT: Homodimer. The active form is probably a hexamer composed
CC       of 3 homodimers. {ECO:0000269|PubMed:16939420}.
CC   -!- INTERACTION:
CC       Self; NbExp=7; IntAct=EBI-749195, EBI-749195;
CC       Q9H8Y8:GORASP2; NbExp=3; IntAct=EBI-749195, EBI-739467;
CC       P11908:PRPS2; NbExp=6; IntAct=EBI-749195, EBI-4290895;
CC       P11908-2:PRPS2; NbExp=3; IntAct=EBI-749195, EBI-12063547;
CC       Q14558:PRPSAP1; NbExp=11; IntAct=EBI-749195, EBI-724449;
CC       O60256:PRPSAP2; NbExp=5; IntAct=EBI-749195, EBI-724960;
CC       Q9NZD8:SPG21; NbExp=6; IntAct=EBI-749195, EBI-742688;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P60891-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P60891-2; Sequence=VSP_056028;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Note=Phosphoribosyl pyrophosphate synthetase I deficiency
CC       is a rare condition caused by mutations in PRPS1 that lead to
CC       variable disease phenotypes including optic atrophy, retinitis
CC       pigmentosa, ataxia, peripheral neuropathy and hearing loss.
CC       {ECO:0000269|PubMed:25491489}.
CC   -!- DISEASE: Phosphoribosylpyrophosphate synthetase superactivity
CC       (PRPS1 superactivity) [MIM:300661]: Familial disorder
CC       characterized by excessive purine production, gout and uric acid
CC       urolithiasis. {ECO:0000269|PubMed:7593598, ECO:0000269|Ref.12}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, X-linked recessive, 5
CC       (CMTX5) [MIM:311070]: A form of Charcot-Marie-Tooth disease, a
CC       disorder of the peripheral nervous system, characterized by
CC       progressive weakness and atrophy, initially of the peroneal
CC       muscles and later of the distal muscles of the arms. Charcot-
CC       Marie-Tooth disease is classified in two main groups on the basis
CC       of electrophysiologic properties and histopathology: primary
CC       peripheral demyelinating neuropathies characterized by severely
CC       reduced motor nerve conduction velocities (NCVs) (less than 38m/s)
CC       and segmental demyelination and remyelination, and primary
CC       peripheral axonal neuropathies characterized by normal or mildly
CC       reduced NCVs and chronic axonal degeneration and regeneration on
CC       nerve biopsy. {ECO:0000269|PubMed:17701900}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: ARTS syndrome (ARTS) [MIM:301835]: A disorder
CC       characterized by mental retardation, early-onset hypotonia,
CC       ataxia, delayed motor development, hearing impairment, and optic
CC       atrophy. Susceptibility to infections, especially of the upper
CC       respiratory tract, can result in early death.
CC       {ECO:0000269|PubMed:17701896}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, X-linked, 1 (DFNX1) [MIM:304500]: A form of
CC       deafness characterized by progressive, severe-to-profound
CC       sensorineural hearing loss in males. Females manifest mild to
CC       moderate hearing loss. {ECO:0000269|PubMed:20021999}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=A mutation in PRPS1 has been found in a patient with
CC       a phenotype that bridges that of PRSPS1 superactivity and ARTS
CC       syndrome with uric acid overproduction without gout but with
CC       recurrent infections, sensorineural hearing loss and motor
CC       neuropathy. The intermadiate phenotype may be because Leu-142
CC       variant affects both allosteric sites that are involved in
CC       inhibition of PRPS1 and the ATP-binding site, which suggests that
CC       this substitution can result both in a gain-of-function and loss-
CC       of-function of PRPP synthetase. {ECO:0000269|PubMed:22246954}.
CC   -!- SIMILARITY: Belongs to the ribose-phosphate pyrophosphokinase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X15331; CAA33386.1; -; mRNA.
DR   EMBL; D00860; BAA00733.1; -; mRNA.
DR   EMBL; AK297968; BAG60278.1; -; mRNA.
DR   EMBL; AK312706; BAG35584.1; -; mRNA.
DR   EMBL; AL137787; CAI42173.1; -; Genomic_DNA.
DR   EMBL; AL772400; CAI42173.1; JOINED; Genomic_DNA.
DR   EMBL; AL772400; CAI41098.1; -; Genomic_DNA.
DR   EMBL; AL137787; CAI41098.1; JOINED; Genomic_DNA.
DR   EMBL; CH471120; EAX02709.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02710.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02711.1; -; Genomic_DNA.
DR   EMBL; BC001605; AAH01605.1; -; mRNA.
DR   CCDS; CCDS14529.1; -. [P60891-1]
DR   PIR; JX0159; KIHUR1.
DR   RefSeq; NP_001191331.1; NM_001204402.1.
DR   RefSeq; NP_002755.1; NM_002764.3. [P60891-1]
DR   UniGene; Hs.56; -.
DR   PDB; 2H06; X-ray; 2.20 A; A/B=1-318.
DR   PDB; 2H07; X-ray; 2.20 A; A/B=1-318.
DR   PDB; 2H08; X-ray; 2.50 A; A/B=1-318.
DR   PDB; 2HCR; X-ray; 2.20 A; A/B=1-318.
DR   PDB; 3EFH; X-ray; 2.60 A; A/B=1-318.
DR   PDB; 3S5J; X-ray; 2.02 A; A/B=1-318.
DR   PDB; 4F8E; X-ray; 2.27 A; A/B=1-318.
DR   PDB; 4LYG; X-ray; 3.00 A; A/B=1-318.
DR   PDB; 4LZN; X-ray; 2.14 A; A/B=1-318.
DR   PDB; 4LZO; X-ray; 3.31 A; A/B=1-318.
DR   PDB; 4M0P; X-ray; 2.11 A; A/B=1-318.
DR   PDB; 4M0U; X-ray; 2.74 A; A/B=1-318.
DR   PDBsum; 2H06; -.
DR   PDBsum; 2H07; -.
DR   PDBsum; 2H08; -.
DR   PDBsum; 2HCR; -.
DR   PDBsum; 3EFH; -.
DR   PDBsum; 3S5J; -.
DR   PDBsum; 4F8E; -.
DR   PDBsum; 4LYG; -.
DR   PDBsum; 4LZN; -.
DR   PDBsum; 4LZO; -.
DR   PDBsum; 4M0P; -.
DR   PDBsum; 4M0U; -.
DR   ProteinModelPortal; P60891; -.
DR   SMR; P60891; -.
DR   BioGrid; 111615; 49.
DR   DIP; DIP-61999N; -.
DR   IntAct; P60891; 17.
DR   STRING; 9606.ENSP00000361512; -.
DR   BindingDB; P60891; -.
DR   ChEMBL; CHEMBL2638; -.
DR   iPTMnet; P60891; -.
DR   PhosphoSitePlus; P60891; -.
DR   SwissPalm; P60891; -.
DR   BioMuta; PRPS1; -.
DR   DMDM; 46397477; -.
DR   UCD-2DPAGE; P60891; -.
DR   EPD; P60891; -.
DR   MaxQB; P60891; -.
DR   PaxDb; P60891; -.
DR   PeptideAtlas; P60891; -.
DR   PRIDE; P60891; -.
DR   DNASU; 5631; -.
DR   Ensembl; ENST00000372435; ENSP00000361512; ENSG00000147224. [P60891-1]
DR   GeneID; 5631; -.
DR   KEGG; hsa:5631; -.
DR   UCSC; uc004ene.5; human. [P60891-1]
DR   CTD; 5631; -.
DR   DisGeNET; 5631; -.
DR   GeneCards; PRPS1; -.
DR   GeneReviews; PRPS1; -.
DR   HGNC; HGNC:9462; PRPS1.
DR   MalaCards; PRPS1; -.
DR   MIM; 300661; phenotype.
DR   MIM; 301835; phenotype.
DR   MIM; 304500; phenotype.
DR   MIM; 311070; phenotype.
DR   MIM; 311850; gene.
DR   neXtProt; NX_P60891; -.
DR   OpenTargets; ENSG00000147224; -.
DR   Orphanet; 1187; Lethal ataxia with deafness and optic atrophy.
DR   Orphanet; 411536; Mild phosphoribosylpyrophosphate synthetase superactivity.
DR   Orphanet; 411543; Severe phosphoribosylpyrophosphate synthetase superactivity.
DR   Orphanet; 99014; X-linked Charcot-Marie-Tooth disease type 5.
DR   Orphanet; 90625; X-linked non-syndromic sensorineural deafness type DFN.
DR   PharmGKB; PA33817; -.
DR   eggNOG; KOG1448; Eukaryota.
DR   eggNOG; COG0462; LUCA.
DR   GeneTree; ENSGT00550000074583; -.
DR   HOGENOM; HOG000210451; -.
DR   HOVERGEN; HBG001520; -.
DR   InParanoid; P60891; -.
DR   KO; K00948; -.
DR   OMA; DGEIMVE; -.
DR   OrthoDB; EOG091G0ZG8; -.
DR   PhylomeDB; P60891; -.
DR   TreeFam; TF106366; -.
DR   BioCyc; MetaCyc:HS07410-MONOMER; -.
DR   BRENDA; 2.7.6.1; 2681.
DR   Reactome; R-HSA-73843; 5-Phosphoribose 1-diphosphate biosynthesis.
DR   UniPathway; UPA00087; UER00172.
DR   ChiTaRS; PRPS1; human.
DR   EvolutionaryTrace; P60891; -.
DR   GenomeRNAi; 5631; -.
DR   PRO; PR:P60891; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147224; -.
DR   CleanEx; HS_PRPS1; -.
DR   ExpressionAtlas; P60891; baseline and differential.
DR   Genevisible; P60891; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0002189; C:ribose phosphate diphosphokinase complex; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; IEA:Ensembl.
DR   GO; GO:0016208; F:AMP binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:Ensembl.
DR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004749; F:ribose phosphate diphosphokinase activity; IDA:UniProtKB.
DR   GO; GO:0006015; P:5-phosphoribose 1-diphosphate biosynthetic process; TAS:Reactome.
DR   GO; GO:0006167; P:AMP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0046101; P:hypoxanthine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0009116; P:nucleoside metabolic process; IEA:InterPro.
DR   GO; GO:0006144; P:purine nucleobase metabolic process; IMP:UniProtKB.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006221; P:pyrimidine nucleotide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0034418; P:urate biosynthetic process; IMP:UniProtKB.
DR   CDD; cd06223; PRTases_typeI; 1.
DR   HAMAP; MF_00583_B; RibP_PPkinase_B; 1.
DR   InterPro; IPR000842; PRib_PP_synth_CS.
DR   InterPro; IPR029099; Pribosyltran_N.
DR   InterPro; IPR000836; PRibTrfase_dom.
DR   InterPro; IPR029057; PRTase-like.
DR   InterPro; IPR005946; Rib-P_diPkinase.
DR   Pfam; PF14572; Pribosyl_synth; 1.
DR   Pfam; PF13793; Pribosyltran_N; 1.
DR   SUPFAM; SSF53271; SSF53271; 1.
DR   TIGRFAMs; TIGR01251; ribP_PPkin; 1.
DR   PROSITE; PS00114; PRPP_SYNTHASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Charcot-Marie-Tooth disease; Complete proteome; Deafness;
KW   Direct protein sequencing; Disease mutation; Gout; Kinase; Magnesium;
KW   Mental retardation; Metal-binding; Neurodegeneration; Neuropathy;
KW   Non-syndromic deafness; Nucleotide biosynthesis; Nucleotide-binding;
KW   Polymorphism; Reference proteome; Retinitis pigmentosa; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.8}.
FT   CHAIN         2    318       Ribose-phosphate pyrophosphokinase 1.
FT                                /FTId=PRO_0000141071.
FT   NP_BIND      96    101       ATP.
FT   REGION      212    227       Binding of phosphoribosylpyrophosphate.
FT                                {ECO:0000255}.
FT   METAL       128    128       Magnesium. {ECO:0000255}.
FT   METAL       130    130       Magnesium. {ECO:0000255}.
FT   METAL       139    139       Magnesium. {ECO:0000255}.
FT   METAL       143    143       Magnesium. {ECO:0000255}.
FT   BINDING     130    130       ATP.
FT   VAR_SEQ       1     67       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056028.
FT   VARIANT      16     16       S -> P (probable disease-associated
FT                                mutation found in patients with
FT                                phosphoribosyl pyrophosphate synthetase I
FT                                deficiency; dbSNP:rs869025594).
FT                                {ECO:0000269|PubMed:25491489}.
FT                                /FTId=VAR_072719.
FT   VARIANT      43     43       E -> D (in CMTX5; dbSNP:rs80338731).
FT                                {ECO:0000269|PubMed:17701900}.
FT                                /FTId=VAR_036941.
FT   VARIANT      52     52       D -> H (in PRPS1 superactivity;
FT                                dbSNP:rs137852542).
FT                                {ECO:0000269|PubMed:7593598}.
FT                                /FTId=VAR_016044.
FT   VARIANT      65     65       D -> N (in DFNX1; dbSNP:rs180177151).
FT                                {ECO:0000269|PubMed:20021999}.
FT                                /FTId=VAR_063522.
FT   VARIANT      87     87       A -> T (in DFNX1; dbSNP:rs180177152).
FT                                {ECO:0000269|PubMed:20021999}.
FT                                /FTId=VAR_063523.
FT   VARIANT     114    114       N -> S (in PRPS1 superactivity;
FT                                dbSNP:rs137852540).
FT                                {ECO:0000269|PubMed:7593598,
FT                                ECO:0000269|Ref.12}.
FT                                /FTId=VAR_004163.
FT   VARIANT     115    115       M -> T (in CMTX5; dbSNP:rs80338732).
FT                                {ECO:0000269|PubMed:17701900}.
FT                                /FTId=VAR_036942.
FT   VARIANT     129    129       L -> I (in PRPS1 superactivity;
FT                                dbSNP:rs137852543).
FT                                {ECO:0000269|PubMed:7593598}.
FT                                /FTId=VAR_016045.
FT   VARIANT     133    133       Q -> P (in ARTS; dbSNP:rs80338675).
FT                                {ECO:0000269|PubMed:17701896}.
FT                                /FTId=VAR_036943.
FT   VARIANT     142    142       V -> L (found in a patient with an
FT                                intermediate phenotype between ARTS and
FT                                PRPS1 superactivity; normal PRPP
FT                                synthetase activity in fibroblasts; loss
FT                                of activity in erythrocytes).
FT                                {ECO:0000269|PubMed:22246954}.
FT                                /FTId=VAR_078489.
FT   VARIANT     152    152       L -> P (in ARTS; dbSNP:rs80338676).
FT                                {ECO:0000269|PubMed:17701896}.
FT                                /FTId=VAR_036944.
FT   VARIANT     183    183       D -> H (in PRPS1 superactivity;
FT                                dbSNP:rs137852541).
FT                                {ECO:0000269|PubMed:7593598,
FT                                ECO:0000269|Ref.12}.
FT                                /FTId=VAR_004164.
FT   VARIANT     190    190       A -> V (in PRPS1 superactivity;
FT                                dbSNP:rs137852544).
FT                                {ECO:0000269|PubMed:7593598}.
FT                                /FTId=VAR_016046.
FT   VARIANT     193    193       H -> Q (in PRPS1 superactivity;
FT                                dbSNP:rs137852545).
FT                                {ECO:0000269|PubMed:7593598}.
FT                                /FTId=VAR_016047.
FT   VARIANT     203    203       D -> H (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036593.
FT   VARIANT     219    219       V -> G (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036594.
FT   VARIANT     231    231       H -> D (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036595.
FT   VARIANT     290    290       I -> T (in DFNX1; dbSNP:rs180177153).
FT                                {ECO:0000269|PubMed:20021999}.
FT                                /FTId=VAR_063524.
FT   VARIANT     306    306       G -> R (in DFNX1; dbSNP:rs180177154).
FT                                {ECO:0000269|PubMed:20021999}.
FT                                /FTId=VAR_063525.
FT   MUTAGEN     132    132       S->A: Reduces catalytic activity.
FT                                {ECO:0000269|PubMed:16939420}.
FT   MUTAGEN     132    132       S->F: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:16939420}.
FT   MUTAGEN     144    144       N->H: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:16939420}.
FT   MUTAGEN     146    146       Y->F: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:16939420}.
FT   MUTAGEN     146    146       Y->M: Reduces catalytic activity.
FT                                {ECO:0000269|PubMed:16939420}.
FT   CONFLICT     82     82       A -> G (in Ref. 3; BAG35584).
FT                                {ECO:0000305}.
FT   CONFLICT    122    122       D -> G (in Ref. 3; BAG35584).
FT                                {ECO:0000305}.
FT   CONFLICT    278    278       E -> G (in Ref. 3; BAG35584).
FT                                {ECO:0000305}.
FT   STRAND        4      8       {ECO:0000244|PDB:3S5J}.
FT   HELIX        14     22       {ECO:0000244|PDB:3S5J}.
FT   STRAND       30     34       {ECO:0000244|PDB:3S5J}.
FT   STRAND       36     38       {ECO:0000244|PDB:2H06}.
FT   STRAND       40     44       {ECO:0000244|PDB:3S5J}.
FT   STRAND       52     56       {ECO:0000244|PDB:3S5J}.
FT   HELIX        63     79       {ECO:0000244|PDB:3S5J}.
FT   STRAND       83     91       {ECO:0000244|PDB:3S5J}.
FT   TURN         93     96       {ECO:0000244|PDB:3S5J}.
FT   STRAND      101    104       {ECO:0000244|PDB:2H06}.
FT   HELIX       108    119       {ECO:0000244|PDB:3S5J}.
FT   STRAND      122    128       {ECO:0000244|PDB:3S5J}.
FT   HELIX       132    137       {ECO:0000244|PDB:3S5J}.
FT   STRAND      142    145       {ECO:0000244|PDB:3S5J}.
FT   HELIX       148    158       {ECO:0000244|PDB:3S5J}.
FT   HELIX       162    164       {ECO:0000244|PDB:3S5J}.
FT   STRAND      166    171       {ECO:0000244|PDB:3S5J}.
FT   HELIX       172    174       {ECO:0000244|PDB:3S5J}.
FT   HELIX       175    185       {ECO:0000244|PDB:3S5J}.
FT   STRAND      188    194       {ECO:0000244|PDB:3S5J}.
FT   STRAND      205    209       {ECO:0000244|PDB:3S5J}.
FT   STRAND      214    225       {ECO:0000244|PDB:3S5J}.
FT   HELIX       227    238       {ECO:0000244|PDB:3S5J}.
FT   STRAND      242    251       {ECO:0000244|PDB:3S5J}.
FT   TURN        254    256       {ECO:0000244|PDB:4LYG}.
FT   HELIX       257    263       {ECO:0000244|PDB:3S5J}.
FT   STRAND      267    272       {ECO:0000244|PDB:3S5J}.
FT   HELIX       278    282       {ECO:0000244|PDB:3S5J}.
FT   STRAND      287    290       {ECO:0000244|PDB:3S5J}.
FT   HELIX       293    305       {ECO:0000244|PDB:3S5J}.
FT   HELIX       310    313       {ECO:0000244|PDB:3S5J}.
SQ   SEQUENCE   318 AA;  34834 MW;  46D017E969908BA0 CRC64;
     MPNIKIFSGS SHQDLSQKIA DRLGLELGKV VTKKFSNQET CVEIGESVRG EDVYIVQSGC
     GEINDNLMEL LIMINACKIA SASRVTAVIP CFPYARQDKK DKSRAPISAK LVANMLSVAG
     ADHIITMDLH ASQIQGFFDI PVDNLYAEPA VLKWIRENIS EWRNCTIVSP DAGGAKRVTS
     IADRLNVDFA LIHKERKKAN EVDRMVLVGD VKDRVAILVD DMADTCGTIC HAADKLLSAG
     ATRVYAILTH GIFSGPAISR INNACFEAVV VTNTIPQEDK MKHCSKIQVI DISMILAEAI
     RRTHNGESVS YLFSHVPL
//
